We'll know more about the company's medium-term prospects by the end of the year.
The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...
There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...
Live Science on MSN
$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
Researchers have developed a modified CRISPR gene-editing tool with potential to silence the extra chromosome causing Down ...
Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results